Last reviewed · How we verify
NCT04309240
Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
Phase 3 trial testing Rivaroxaban in Rivaroxaban in 204 participants. Status unknown.
8 March 2022
Quick facts
| Lead sponsor | LiuZhou People's Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 204 |
| Start date | 8 March 2020 |
| Primary completion | 8 March 2022 |
| Estimated completion | 8 March 2022 |
Drugs / interventions tested
- Rivaroxaban (rivaroxaban) — full drug profile →
Conditions studied
- Rivaroxaban — all drugs for Rivaroxaban →
- Thromboprophylaxis — all drugs for Thromboprophylaxis →
- Cancer — all drugs for Cancer →
Sponsor
LiuZhou People's Hospital
Who can join
Adults 18 to 75, any sex, with Rivaroxaban or Thromboprophylaxis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rivaroxaban has been developed in the various clinical settings.Although cancer-associated DVT or PE was included in previously programs, limited patients of the total populations were cancer patients with totally implantable access ports in these studies. In this sense, investigators feel that new oral anticoagulants should be re-investigated in this highly specific patients group.Therefore, investigators are planning to conduct a prospective study to estimate the efficacy and safety of rivaroxaban for thromboprophylaxis in high-risk cancer patients with totally implantable access ports.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04309240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban
Trials testing the same drug.
- NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
- NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
- NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting
Other recruiting trials for Rivaroxaban
Currently open trials in the same condition.
- NCT06978439 — Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease · Phase 4 · recruiting
- NCT06993636 — Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years · recruiting
Other LiuZhou People's Hospital trials
Trials by the same sponsor.
- NCT06576024 — Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04309240 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LiuZhou People's Hospital
- Last refreshed: 16 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04309240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing